II. Indications
- Early Type II Diabetes Mellitus Oral Agent
- Elevated postprandial Glucose
- Consider if only used intermittently for pre-meal Hyperglycemia
III. Contraindications
- Sulfa Hypersensitivity
- Chronic Kidney Disease Stage 5 (eGFR <15 ml/min)
IV. Mechanism
- Insulin secretogogue
- Benzoic acid derived from Sulfonylureas
- Directly stimulates pancreatic beta cells (Similar to Sulfonylureas)
- Binds different sites from Sulfonylureas (Sulfonylurea Receptors 1, 1A and 1B)
- Closes ATP sensitive K+ channels
- Results in Insulin secretion
- Effects
- Predominately effects postprandial Glucose
- Faster oral absorption and onset than Sulfonylureas
- Shorter duration of binding and shorter effect than Sulfonylureas
V. Medications
- Repaglinide (Prandin)
- Nateglinide (Starlix)
- Significantly weaker activity compared with Repaglinide
VI. Dosing
VIII. Adverse Effects
- Hypoglycemia (lower risk than Sulfonylureas)
IX. Efficacy
- Lowers HBA1C by 0.5 to 1%
- Advantages in comparison to Sulfonylureas
- Low risk of Hypoglycemia (2.4%) than Sulfonylureas
- Effect depends on Ambient Blood Glucose levels
- No significant gastrointestinal side effects
- Minimal weight gain
- No lab monitoring required
- No significant Drug Interactions
- No Lactic Acidosis
- No adjustments needed (other than per meal)
- No adjustment in Congestive Heart Failure
- No adjustment for age
- No adjustment in Renal Insufficiency
- Disadvantages in comparison to Sulfonylureas
- Two to three times as expensive as Sulfonylureas
Images: Related links to external sites (from Bing)
Related Studies
repaglinide (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
REPAGLINIDE 0.5 MG TABLET | Generic | $0.11 each |
REPAGLINIDE 1 MG TABLET | Generic | $0.12 each |
REPAGLINIDE 2 MG TABLET | Generic | $0.13 each |
nateglinide (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NATEGLINIDE 120 MG TABLET | Generic | $0.30 each |
NATEGLINIDE 60 MG TABLET | Generic | $0.27 each |